|
|
Vaccine Detail
|
Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1 |
| Vaccine Information |
- Vaccine Name: Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007007
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- EGFR
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Brain Cancer (NCT02149225). A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens (NCIT_C116331).
|
| Host Response |
|
|
| References |
NCIT_C116331: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116331]
NCT02149225: [https://clinicaltrials.gov/show/NCT02149225/]
|
|
